Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03570749 · OUTCOME

Percentage of Participants Achieving ClinRO Measure for Eyebrow (EB) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EB Hair Loss ≥ 2 at Baseline) - Phase 3 Open-Label Addendum

A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata · Source last updated 2026-04-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
Week 52

What was measured

ClinRO is a clinician reported assessment which measures a participant's EB hair loss. It is comprised of 4 category response options: 0 = EB have full coverage and no areas of hair loss; 1 = There are minimal gaps in EB hair and distribution is even; 2 = There are significant gaps in EB hair or distribution is not even; 3 = No notable EB.

Analysis population: All randomized phase 3 open-label addendum participants with baseline ClinRO measure for EB Hair Loss ≥ 2 and who had evaluable data for this outcome measure.

Groups in this outcome

4 mg Baricitinib Phase 3 Open-Label Addendum

Participants who received one 4 mg Baricitinib tablet administered orally QD.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
4 mg Baricitinib Phase 3 Open-Label Addendum4

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
4 mg Baricitinib Phase 3 Open-Label Addendum50.0Not reported15.085.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        15.0
        upper Limit
        85.0
        value
        50.0
denoms
  1. counts
    1. group Id
      OG000
      value
      4
    units
    Participants
description
ClinRO is a clinician reported assessment which measures a participant's EB hair loss. It is comprised of 4 category response options: 0 = EB have full coverage and no areas of hair loss; 1 = There are minimal gaps in EB hair and distribution is even; 2 = There are significant gaps in EB hair or distribution is not even; 3 = No notable EB.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants who received one 4 mg Baricitinib tablet administered orally QD.
    id
    OG000
    title
    4 mg Baricitinib Phase 3 Open-Label Addendum
param Type
NUMBER
population Description
All randomized phase 3 open-label addendum participants with baseline ClinRO measure for EB Hair Loss ≥ 2 and who had evaluable data for this outcome measure.
reporting Status
POSTED
time Frame
Week 52
title
Percentage of Participants Achieving ClinRO Measure for Eyebrow (EB) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EB Hair Loss ≥ 2 at Baseline) - Phase 3 Open-Label Addendum
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice